18.50p-0.50 (-2.63%)23 Feb 2024, 16:14
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Redx Pharma PLC Fundamentals

Company NameRedx Pharma PLCLast Updated2024-02-23
Shares in Issue388.986 mMarket Cap£71.96 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.10EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.6897Debt Equity Ratio0.3797
Asset Equity Ratio7.6411Cash Equity Ratio5.3925
Quick Ratio1.0815Current Ratio1.11
Price To Book Value22.0264ROCE0

Redx Pharma PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Redx Pharma PLC Company Financials

Tangible Assets£1.94 m£2.70 m£3.33 m
Intangible Assets£394,000.00£400,000.00£405,000.00
Total Fixed Assets£2.33 m£3.10 m£3.73 m
Debtors£4.63 m£4.59 m£5.58 m
Cash & Equivalents£18.09 m£53.85 m£29.55 m
Other Assets000
Total Assets£25.64 m£62.48 m£39.55 m
Creditors within 1 year£21.01 m£27.20 m£9.59 m
Creditors after 1 year£1.27 m£1.95 m£16.82 m
Other Liabilities000
Total Liabilities£22.28 m£29.16 m£26.41 m
Net assets£3.35 m£33.32 m£13.13 m
Called up share capital£3.35 m£3.35 m£2.75 m
Share Premium£99.50 m£99.50 m£66.30 m
Profit / Loss-£32.79 m-£17.80 m-£21.44 m
Other Equity£3.35 m£33.32 m£13.13 m
Preference & Minorities000
Total Capital Employed£3.35 m£33.32 m£13.13 m
Debt Ratio£0.28£0.06£0.56
Assets / Equity7.64117.64117.6411
Cash / Equity5.39255.39255.3925
Cash Flow202320222021
Cash from operating activities-£34.75 m-£8.47 m-£21.38 m
Cashflow before financing-£35.56 m£24.51 m£2.76 m
Increase in Cash-£35.76 m£24.27 m£2.01 m
Turnover£4.20 m£18.69 m£10.04 m
Cost of sales000
Gross Profit000
Operating Profit-£33.82 m-£16.27 m-£19.75 m
Pre-Tax profit-£32.79 m-£17.80 m-£21.44 m

Redx Pharma PLC Company Background

ActivitiesRedx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others. The firm operates geographically in the UK and Ireland. Revenue is generated from; Scientific programmes and research collaboration, Research collaboration, and Research and preclinical development services.
Latest Interim Date17 May 2023
Latest Fiscal Year End Date15 Dec 2023

Redx Pharma PLC Directors

2021-06-01Mr. Iain Gladstone RossNon-Executive Director,Chairman
2018-02-19Dr. Frank Murdoch ArmstrongNon-Executive Director,Chairman
2024-02-17Mr. Peter Eric Presland Non-Executive Director
2018-02-19Mr. Norman MolyneuxNon-Executive Director
2018-02-19Dr. Neil David MurrayExecutive Director,Chief Executive Officer
2018-02-19Dr. Peter JacksonNon-Executive Director
2017-03-30Dr. Derek LindsayExecutive Director,Chief Operating Officer
2017-03-30Mr. Philip John TotteyExecutive Director,Chief Financial Officer
2017-04-20Mr. Peter McPartlandNon-Executive Director
2024-02-17Dr. Bernhard Jurgen KirschbaumNon-Executive Director
2024-02-17Dr. Jane Veronica Griffiths Non-Executive Director,Chairman
2020-03-17Mr. Dominic Nicholas Jackson Executive Director,Chief Financial Officer
2024-02-17Mrs. Lisa Mary Whewell AnsonExecutive Director,Chief Executive Officer
2021-03-02Dr. James Robert MeadExecutive Director,Chief Financial Officer
2024-02-17Mrs. Sarah Gordon WildNon-Executive Director
2024-02-17Dr. Robert Andrew Donald Scott, M.D.Non-Executive Director

Redx Pharma PLC Contact Details

Company NameRedx Pharma PLC
AddressBlock 33, Mereside, Alderley Park, Macclesfield, SK10 4TG
Telephone+44 1625469900

Redx Pharma PLC Advisors

StockbrokerWG Partners
Financial PR AdviserConsilium Strategic Communications
Phone+44 2037095700
Nominated AdviserCantor Fitzgerald Europe
Phone +44 2078947895
StockbrokerCantor Fitzgerald Europe
Phone+44 2078947895
SolicitorDWF LLP
Phone+44 1612283702
Fax+44 1618352407
RegistrarEquiniti Ltd.
Phone+44 1214157082